866-997-4948(US-Canada Toll Free)

Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 66 Pages

Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2017

Summary

Toll Like Receptor 8 (CD288 or TLR8) - Toll-like receptor 8 is a protein encoded by the TLR8 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response.

Toll Like Receptor 8 (CD288 or TLR8) pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 3, 7 and 4 respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Dermatology, Gastrointestinal, Musculoskeletal Disorders and Respiratory which include indications Cutaneous T-Cell Lymphoma, Solid Tumor, Systemic Lupus Erythematosus, Actinic (Solar) Keratosis, Allergic Rhinitis, Autoimmune Disorders, Colon Cancer, Colorectal Cancer, Crohns Disease (Regional Enteritis), Dermatomyositis, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Hepatitis B, Pancreatic Cancer, Peritoneal Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Sicca Syndrome (Sjogren), Ulcerative Colitis and Warts.

The latest report Toll Like Receptor 8 - Pipeline Review, H2 2017, outlays comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 8 (CD288 or TLR8)
- The report reviews Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics and enlists all their major and minor projects
- The report assesses Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 8 (CD288 or TLR8)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 8 (CD288 or TLR8) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Toll Like Receptor 8 (CD288 or TLR8) - Overview 7
Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 12
Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Assessment 15
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Toll Like Receptor 8 (CD288 or TLR8) - Companies Involved in Therapeutics Development 21
AstraZeneca Plc 21
Celgene Corp 21
Dynavax Technologies Corp 22
Eisai Co Ltd 22
Galderma SA 23
Gilead Sciences Inc 23
Idera Pharmaceuticals Inc 24
Janus Biotherapeutics Inc 24
MedImmune LLC 24
Nektar Therapeutics 25
Vivelix Pharmaceuticals Ltd 25
Toll Like Receptor 8 (CD288 or TLR8) - Drug Profiles 26
854-A - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
durvalumab + MEDI-9197 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
DV-1001 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
E-6742 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
GS-9688 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
IMO-8400 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
IMO-9200 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
JB-6121 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
MEDI-9197 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
motolimod - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
NKTR-262 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
resiquimod - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
RSLV-132 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
VTX-1463 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Toll Like Receptor 8 (CD288 or TLR8) - Dormant Products 51
Toll Like Receptor 8 (CD288 or TLR8) - Discontinued Products 53
Toll Like Receptor 8 (CD288 or TLR8) - Product Development Milestones 54
Featured News & Press Releases 54
Nov 07, 2017: Nektar to Present New On Drug Candidate NKTR-262 At 2017 Society for Immunotherapy of Cancer 32nd Annual Meeting 54
Aug 22, 2016: Resolve Therapeutics Announces Publication Of Clinical Data Demonstrating The Role Of Circulating RNA In Systemic Lupus Erythematosus 54
Jul 12, 2016: Mayo Clinic researchers identify potential immunotherapy drug combination 54
May 26, 2016: Resolve To Present Data On Lupus Studies At International Rheumatology Conference 55
Feb 10, 2016: Resolve Announces Positive Clinical Data From RSLV-132 Lupus Study 55
Dec 05, 2015: Idera Pharmaceuticals Reports Positive Data From Ongoing Phase 1/2 Clinical Trial of IMO-8400 in Patients With Waldenstroms Macroglobulinemia 56
Nov 09, 2015: Idera Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of IMO-8400 in Patients with Dermatomyositis 57
Nov 05, 2015: Idera Pharmaceuticals to Present Phase 1/2 IMO-8400 Clinical Data in Waldenstroms Macroglobulinemia at the 2015 American Society of Hematology Annual Meeting 58
May 18, 2015: Idera Pharmaceuticals Provides Development Update on IMO-9200, an Antagonist of Toll-like Receptors 58
Apr 27, 2015: VentiRx Pharmaceuticals Granted Orphan Drug Designation in the European Union For Motolimod in the Treatment of Ovarian Cancer 60
Apr 01, 2015: Idera Announces FDA Orphan Drug Designation for IMO-8400 for the Treatment of Diffuse Large B-Cell Lymphoma 60
Dec 30, 2014: Idera Provides Key Updates on Clinical Development of IMO-8400 for Treatment of Waldenstroms Macroglobulinemia 61
Dec 08, 2014: Idera Pharmaceuticals Presents Data Supporting IMO-8400 as Novel Therapy for Genetically Defined Forms of B-Cell Lymphoma at Annual ASH Meeting 61
Nov 06, 2014: Idera Pharmaceuticals Announces Upcoming Presentations of Data on IMO-8400 From Oncology Programs at Key Scientific Meetings 63
Oct 14, 2014: Idera Pharmaceuticals Expands Pipeline by Initiating Clinical Development of Proprietary TLR Antagonist Candidate IMO-9200 63
Appendix 65
Methodology 65
Coverage 65
Secondary Research 65
Primary Research 65
Expert Panel Validation 65
Contact Us 65
Disclaimer 66

List of Tables
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Indication, H2 2017 10
Number of Products under Development by Companies, H2 2017 12
Products under Development by Companies, H2 2017 13
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14
Number of Products by Stage and Mechanism of Actions, H2 2017 16
Number of Products by Stage and Route of Administration, H2 2017 18
Number of Products by Stage and Molecule Type, H2 2017 20
Pipeline by AstraZeneca Plc, H2 2017 21
Pipeline by Celgene Corp, H2 2017 22
Pipeline by Dynavax Technologies Corp, H2 2017 22
Pipeline by Eisai Co Ltd, H2 2017 23
Pipeline by Galderma SA, H2 2017 23
Pipeline by Gilead Sciences Inc, H2 2017 23
Pipeline by Idera Pharmaceuticals Inc, H2 2017 24
Pipeline by Janus Biotherapeutics Inc, H2 2017 24
Pipeline by MedImmune LLC, H2 2017 25
Pipeline by Nektar Therapeutics, H2 2017 25
Pipeline by Vivelix Pharmaceuticals Ltd, H2 2017 25
Dormant Products, H2 2017 51
Dormant Products, H2 2017 (Contd..1), H2 2017 52
Discontinued Products, H2 2017 53

List of Figures
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Top 10 Indications, H2 2017 10
Number of Products by Mechanism of Actions, H2 2017 15
Number of Products by Stage and Mechanism of Actions, H2 2017 15
Number of Products by Routes of Administration, H2 2017 17
Number of Products by Stage and Routes of Administration, H2 2017 17
Number of Products by Molecule Types, H2 2017 19
Number of Products by Stage and Top 10 Molecule Types, H2 2017 19

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *